Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Certainty index

Not assessed — no eligible study identified — page 2

Outcomes for which the Institute has identified no eligible study, and therefore issues no certainty rating.

Outcomes not assessed

41 documents · page 2 of 2

Table 1. Outcomes for which no eligible study has been identified, on this page.

QuestionIndicationAnchor outcome
Kisspeptin-10 in gh axisGrowth hormone deficiency and growth-hormone secretagogue pharmacologyPeak stimulated growth hormone
41 outcomes in total. Each carries, on its own page, a statement of the study that would allow a rating to be issued.

page 2 of 2

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.